Skip to main content
. Author manuscript; available in PMC: 2018 Oct 8.
Published in final edited form as: Thromb Res. 2018 Jul 6;169:96–104. doi: 10.1016/j.thromres.2018.07.003

Figure 2: The protease inhibitor ritonavir dysregulates human platelet proinflammatory mediator production and release in vitro.

Figure 2:

1.1×108/mL of washed human platelets were treated with vehicle (0.1% DMSO) or the indicated doses of ritonavir. Supernatant concentrations of A. prostaglandin E2 (PGE2), B. the thromboxane A2 metabolite thromboxane B2 (TXB2), C. soluble CD40L (sCD40L), and D. Platelet factor 4 (PF4) were determined via enzyme immunoassay. E. 1.1 × 106 platelets/mL were stained for CD62P. Platelets were gated on based on their size and granularity via forward and side scatter on a log scale. n≥6 for each immunoassay. n≥3 for flow cytometry. Symbols in A–D represent unique donors. Error bars indicate SEM. Statistics were performed using paired two-tailed t-tests. *p<0.05.